Company intelligence / Profile preview

XyloCor Therapeutics

King of Prussia, Pennsylvania, United Statesxylocor.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 2

Overview

XyloCor's lead product XC001 (encoberminogene rezmadenovec) has completed Phase 2 portion of its Phase 1/2 clinical trial (EXACT) with positive results. The 12-month data showed durable improvements across multiple efficacy measures, including continued improvement in total exercise duration and reductions in ischemic burden and ischemic symptoms. The treatment met both safety and efficacy objectives with no safety issues related to drug product or unexpected serious adverse events.[8][9]

Therapeutic areas: Cardiovascular
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

2 assets

encoberminogene rezmadenovec

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on XyloCor Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XyloCor Therapeutics.

Explore the full profile